Progenics Pharmaceuticals Company Profile (NASDAQ:PGNX)

About Progenics Pharmaceuticals

Progenics Pharmaceuticals logoProgenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company's EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces an automated Bone Scan Index quantification. The Company's clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ([18F] DCFPyL), 1095 and PSMA ADC. The Company's partnered products include Relistor-Subcutaneous injection, Relistor-Oral Tablets and PRO 140.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: PGNX
  • CUSIP: 74318710
Key Metrics:
  • Previous Close: $6.06
  • 50 Day Moving Average: $6.41
  • 200 Day Moving Average: $5.30
  • 52-Week Range: $3.61 - $8.37
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -33.67
  • P/E Growth: 0.16
  • Market Cap: $424.11M
  • Outstanding Shares: 69,985,000
  • Beta: 2.34
Profitability:
  • Net Margins: -203.56%
  • Return on Equity: -41.76%
  • Return on Assets: -27.95%
Debt:
  • Current Ratio: 5.14%
  • Quick Ratio: 5.14%
Additional Links:
Companies Related to Progenics Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Progenics Pharmaceuticals (NASDAQ:PGNX) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.75 (77.39% upside)

Analysts' Ratings History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Show:
DateFirmActionRatingPrice TargetDetails
8/5/2016Brean CapitalSet Price TargetBuy$14.00View Rating Details
7/22/2016Needham & Company LLCReiterated RatingBuy$11.00View Rating Details
7/20/2016BTIG ResearchReiterated RatingBuy$9.00View Rating Details
6/10/2016Jefferies GroupReiterated RatingBuyView Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Progenics Pharmaceuticals (NASDAQ:PGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/4/2016Q216($0.13)($0.08)$6.33 million$8.50 millionViewN/AView Earnings Details
5/5/2016Q116($0.13)($0.18)$3.27 million$2.50 millionViewListenView Earnings Details
3/11/2016Q415($0.14)($0.10)$2.25 million$5.10 millionViewListenView Earnings Details
11/9/2015Q315($0.13)($0.14)$2.35 million$1.40 millionViewListenView Earnings Details
8/6/2015Q215($0.15)($0.17)$1.63 million$1.90 millionViewListenView Earnings Details
5/6/2015Q115($0.16)($0.15)$1.30 million$0.25 millionViewN/AView Earnings Details
3/16/2015Q414($0.13)($0.18)$2.87 million($0.57) millionViewN/AView Earnings Details
11/7/2014Q314($0.16)$0.51$2.50 million$41.66 millionViewN/AView Earnings Details
8/8/2014Q214($0.14)($0.17)$2.83 million$1.50 millionViewListenView Earnings Details
5/9/2014Q114($0.15)($0.15)$2.88 million$1.80 millionViewN/AView Earnings Details
3/13/2014Q4($0.19)($0.14)$1.48 million$3.00 millionViewListenView Earnings Details
11/11/2013Q313($0.22)($0.17)$2.00 million$0.90 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.24)($0.24)$1.86 million$1.80 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.19)($0.22)$1.71 million$2.23 millionViewN/AView Earnings Details
3/15/2013Q4 2012($0.31)($0.01)$1.16 million$8.87 millionViewN/AView Earnings Details
11/8/2012Q312($0.30)($0.33)$2.52 million$1.10 millionViewN/AView Earnings Details
8/9/2012($0.32)($0.32)ViewN/AView Earnings Details
5/8/2012($0.33)($0.39)ViewN/AView Earnings Details
11/9/2011($0.33)($0.34)ViewN/AView Earnings Details
8/9/2011($0.25)$1.64ViewN/AView Earnings Details
5/10/2011($0.51)($0.69)ViewN/AView Earnings Details
3/15/2011($0.57)($0.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Progenics Pharmaceuticals (NASDAQ:PGNX)
Current Year EPS Consensus Estimate: $0.15 EPS
Next Year EPS Consensus Estimate: $-0.18 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.12)($0.12)($0.12)
Q2 20161($0.11)($0.11)($0.11)
Q3 20161$0.52$0.52$0.52
Q4 20161($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Progenics Pharmaceuticals (NASDAQ:PGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Insider Ownership Percentage: 5.48%
Institutional Ownership Percentage: 84.22%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/13/2015Robert J IsraelEVPSell3,000$7.00$21,000.00View SEC Filing  
3/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/3/2015Robert J IsraelEVPSell5,000$6.49$32,450.00View SEC Filing  
1/12/2015Robert J IsraelEVPSell2,000$7.06$14,120.00View SEC Filing  
12/11/2014Robert J IsraelEVPSell3,000$7.07$21,210.00View SEC Filing  
11/21/2014Robert J IsraelEVPSell9,000$7.00$63,000.00View SEC Filing  
11/13/2014Robert J IsraelEVPSell10,000$6.83$68,300.00View SEC Filing  
11/11/2014Robert J IsraelEVPSell5,000$6.53$32,650.00View SEC Filing  
7/21/2014Healthcare Master Fun BroadfinMajor ShareholderBuy1,625,436$4.60$7,477,005.60View SEC Filing  
7/18/2014Healthcare Master Fun BroadfinMajor ShareholderBuy388,200$4.73$1,836,186.00View SEC Filing  
7/17/2014Healthcare Master Fun BroadfinMajor ShareholderBuy436,884$4.48$1,957,240.32View SEC Filing  
7/16/2014Healthcare Master Fun BroadfinMajor ShareholderBuy411,693$4.48$1,844,384.64View SEC Filing  
7/18/2013Robert J IsraelVPSell5,000$6.33$31,650.00View SEC Filing  
2/27/2013Mark Robert BakerCEOBuy1,262$2.72$3,432.64View SEC Filing  
1/22/2013Mark Robert BakerCEOBuy1,215$2.82$3,426.30View SEC Filing  
12/26/2012Mark Robert BakerCEOBuy1,142$3.01$3,437.42View SEC Filing  
11/28/2012Mark Robert BakerCEOBuy1,607$2.13$3,422.91View SEC Filing  
11/19/2012Mark Robert BakerCEOBuy11,800$1.96$23,128.00View SEC Filing  
11/16/2012Mark Robert BakerCEOBuy49,793$1.82$90,623.26View SEC Filing  
11/15/2012Mark Robert BakerCEOBuy48,833$1.69$82,527.77View SEC Filing  
10/24/2012Mark Robert BakerCEOBuy1,162$2.96$3,439.52View SEC Filing  
9/26/2012Mark Robert BakerCEOBuy1,036$3.32$3,439.52View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Progenics Pharmaceuticals (NASDAQ:PGNX)
DateHeadline
News IconNews review of 2 biotech stocks: Immunomedics (NASDAQ:IMMU), Progenics Pharmaceuticals (NASDAQ:PGNX) - The Voice Registrar (NASDAQ:PGNX)
voiceregistrar.com - September 23 at 11:31 AM
capitalcube.com logoProgenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PGNX-US : September 23, 2016 (NASDAQ:PGNX)
www.capitalcube.com - September 23 at 11:31 AM
News IconAnalysts' Consensus Opinions for: Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) , Sorrento Therapeutics, Inc ... - Wall Street Times (press release) (NASDAQ:PGNX)
www.wallstreetnews24.com - September 22 at 6:26 PM
News IconProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX) earnings expectations - The Independent Republic (NASDAQ:PGNX)
theindependentrepublic.com - September 22 at 6:26 PM
capitalcube.com logoProgenics Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PGNX) : September 14, 2016 (NASDAQ:PGNX)
www.capitalcube.com - September 14 at 6:54 PM
capitalcube.com logoProgenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : September 13, 2016 (NASDAQ:PGNX)
www.capitalcube.com - September 13 at 11:39 AM
News IconTwo Biotechnology Names Are Hot: Agenus Inc. (AGEN), Progenics Pharmaceuticals, Inc. (PGNX) - The Independent Republic (NASDAQ:PGNX)
theindependentrepublic.com - September 12 at 11:23 AM
News IconValeant Pharmaceuticals, Progenics Pharmaceuticals: Commercially Launched FDA Approved Relistor Tablets (NASDAQ:PGNX)
larampadinapoli.com - September 9 at 6:22 PM
News IconThe Statistics Don't Lie: Progenics Pharmaceuticals, Incorporated (NASDAQ:PGNX) Earnings Preview - The Voice Registrar (NASDAQ:PGNX)
voiceregistrar.com - September 9 at 11:30 AM
News IconBiotech Companies To Look Out For: Progenics Pharmaceuticals, Inc. (PGNX), Gilead Sciences Inc. (GILD) - National Daily Press (NASDAQ:PGNX)
www.nationaldailypress.com - September 9 at 11:30 AM
bidnessetc.com logoValeant Pharmaceuticals, Progenics Pharmaceuticals: Commercially Launched FDA Approved Relistor Tablets - Bidness ETC (NASDAQ:PGNX)
www.bidnessetc.com - September 8 at 10:35 AM
globenewswire.com logoProgenics Pharmaceuticals Announces Appointment of Bryce V. Tenbarge as Vice President of Commercial - GlobeNewswire (press release) (NASDAQ:PGNX)
globenewswire.com - September 7 at 6:53 PM
News IconNews review of 2 biotech stocks: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), CTI BioPharma Corp. (NASDAQ ... - The Voice Registrar (NASDAQ:PGNX)
voiceregistrar.com - September 7 at 6:53 PM
rttnews.com logoValeant And Progenics Announce U.S. Commercial Launch Of Relistor Tablet (NASDAQ:PGNX)
www.rttnews.com - September 7 at 10:18 AM
publicnow.com logoProgenics Pharmaceuticals Announces Appointment of Bryce V. Tenbarge as Vice President of Commercial (NASDAQ:PGNX)
www.publicnow.com - September 7 at 10:18 AM
feeds.benzinga.com logo22 Stocks Moving In Wednesday's Pre-Market Session (NASDAQ:PGNX)
feeds.benzinga.com - September 7 at 9:19 AM
marketwatch.com logoValeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor Tablets (NASDAQ:PGNX)
www.marketwatch.com - September 6 at 6:53 PM
streetinsider.com logoValeant Pharma (VRX), Progenics (PGNX) Announce Commercial Launch of RELISTOR as OIC Treatment (NASDAQ:PGNX)
www.streetinsider.com - September 6 at 6:53 PM
publicnow.com logoValeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets (NASDAQ:PGNX)
www.publicnow.com - September 6 at 6:53 PM
biz.yahoo.com logoPROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:PGNX)
biz.yahoo.com - September 6 at 6:53 PM
News IconTime To Put On The Watch List? - Progenics Pharmaceuticals (NASDAQ:PGNX), Juno Therapeutics (NASDAQ:JUNO) - The Voice Registrar (NASDAQ:PGNX)
voiceregistrar.com - September 6 at 11:32 AM
News IconBiotech Stocks To Put On Your Watch List: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Chimerix, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:PGNX)
voiceregistrar.com - September 2 at 11:37 AM
publicnow.com logoProgenics Pharmaceuticals to Present at the 23rd Annual NewsMakers in the Biotech Industry Conference (NASDAQ:PGNX)
www.publicnow.com - September 2 at 11:37 AM
biz.yahoo.com logoPROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:PGNX)
biz.yahoo.com - September 1 at 9:54 AM
News IconProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Upcoming ... - The Voice Registrar (NASDAQ:PGNX)
voiceregistrar.com - August 30 at 10:06 AM
News IconNews review of 2 biotech stocks: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Biogen Inc. (NASDAQ:BIIB) - The Voice Registrar (NASDAQ:PGNX)
voiceregistrar.com - August 29 at 11:20 AM
News IconBiotech news that matter for investors: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Intrexon Corporation (NYSE ... - The Voice Registrar (NASDAQ:PGNX)
voiceregistrar.com - August 26 at 9:46 AM
marketnewsvideo.com logoShort Interest Increases 10% For PGNX (NASDAQ:PGNX)
www.marketnewsvideo.com - August 25 at 6:52 PM
mysmartrend.com logoProgenics Pharmaceuticals Shares Up 19.4% Since SmarTrend's Buy Recommendation (PGNX) (NASDAQ:PGNX)
www.mysmartrend.com - August 25 at 11:56 AM
News Icon2 Biotech Stocks News And Price Trends: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Immunomedics Inc ... - The Voice Registrar (NASDAQ:PGNX)
voiceregistrar.com - August 19 at 9:50 AM
nasdaq.com logo4 Breakout Stocks to Watch This Week (NASDAQ:PGNX)
www.nasdaq.com - August 18 at 6:59 PM
mysmartrend.com logoProgenics Pharmaceuticals Shares Up 24.3% Since SmarTrend's Buy Recommendation (PGNX) (NASDAQ:PGNX)
www.mysmartrend.com - August 17 at 7:05 PM
News IconThe Key Numbers To Watch From Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)'s Earnings - The Voice Registrar (NASDAQ:PGNX)
voiceregistrar.com - August 17 at 9:50 AM
investing.com logo4 Stocks To Watch: CWEI, EBIO, GIMO, PGNX (NASDAQ:PGNX)
www.investing.com - August 16 at 10:04 AM
finance.yahoo.com logoPROGENICS PHARMACEUTICALS INC Financials (NASDAQ:PGNX)
finance.yahoo.com - August 13 at 6:28 PM
mysmartrend.com logoProgenics Pharmaceuticals Up 21.0% Since SmarTrend Uptrend Call (PGNX) (NASDAQ:PGNX)
www.mysmartrend.com - August 10 at 7:17 PM
News IconHot Biotech Stocks Recap: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Celgene Corporation (NASDAQ:CELG) - The Voice Registrar (NASDAQ:PGNX)
voiceregistrar.com - August 10 at 9:55 AM
News IconHealthcare Shares Need To Consider: Progenics Pharmaceuticals ... - TWN (NASDAQ:PGNX)
thewellesleysnews.com - August 10 at 9:55 AM
streetupdates.com logoAnalysts Actions to Track: Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) , Merck & Company, Inc. (NYSE:MRK) - Street Updates (NASDAQ:PGNX)
www.streetupdates.com - August 10 at 9:55 AM
News IconHigh Volume Healthcare Stocks: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Bristol-Myers Squibb Company ... - TWN (NASDAQ:PGNX)
thewellesleysnews.com - August 10 at 9:55 AM
fortune.com logoWhich way Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) insiders are heading - Review Fortune (NASDAQ:PGNX)
reviewfortune.com - August 10 at 9:55 AM
News IconMost Recent analysts Ratings: Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) - News Oracle (NASDAQ:PGNX)
www.newsoracle.com - August 10 at 9:55 AM
News IconProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX): Power of Chart, We Made 15% Profit In Just 2 Weeks (NASDAQ:PGNX)
www.marketnewscall.com - August 9 at 7:04 PM
News IconAnalyst Stock Ratings: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), General Electric Company (NYSE:GE) - TWN (NASDAQ:PGNX)
thewellesleysnews.com - August 6 at 9:36 AM
equities.com logoProgenics Pharmaceuticals Inc. (PGNX) Jumps 5.9% on August 05 - Equities.com (NASDAQ:PGNX)
www.equities.com - August 6 at 9:36 AM
bloomberg.com logoValeant’s Relistor Said to Draw Interest of Potential Buyers (NASDAQ:PGNX)
www.bloomberg.com - August 5 at 7:01 PM
globenewswire.com logoProgenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results (NASDAQ:PGNX)
globenewswire.com - August 4 at 7:17 PM
streetinsider.com logoForm 8-K PROGENICS PHARMACEUTICAL For: Aug 04 (NASDAQ:PGNX)
www.streetinsider.com - August 4 at 7:17 PM
streetupdates.com logoRecent Analysts Ratings of Stocks: Novavax, Inc. (NASDAQ:NVAX) , Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) - Street Updates (NASDAQ:PGNX)
www.streetupdates.com - August 4 at 10:00 AM
sg.finance.yahoo.com logoProgenics reports 2Q loss (NASDAQ:PGNX)
sg.finance.yahoo.com - August 4 at 10:00 AM

Social

Progenics Pharmaceuticals (NASDAQ:PGNX) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff